Holen Sie sich die Stockscreener-App
57.01
1.55%
0.835
Schlusskurs vom Vortag:
$56.17
Offen:
$56.38
24-Stunden-Volumen:
809.95K
Relative Volume:
0.31
Marktkapitalisierung:
$10.75B
Einnahmen:
$2.83B
Nettoeinkommen (Verlust:
$-1.02B
KGV:
-10.35
EPS:
-5.51
Netto-Cashflow:
$194.14M
1W Leistung:
+10.48%
1M Leistung:
+34.97%
6M Leistung:
+15.63%
1J Leistung:
+9.80%
1-Tages-Spanne:
$55.55
$57.24
1-Wochen-Bereich:
$51.85
$57.24
52-Wochen-Spanne:
$39.97
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
57.01 | 10.01B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
407.29 | 155.07B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
193.40 | 139.43B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
516.22 | 39.41B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.13 | 30.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
141.98 | 26.52B | 15.50B | 1.33B | 2.16B | 7.34 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
10 High PE Stocks Insiders Are Buying - Insider Monkey
Exact Sciences at Bank of America 2025 Healthcare Conference: Strategic Growth and Innovation - Investing.com
Transcript : Exact Sciences Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years - AOL.com
Exact Sciences Earns 2025 Great Place To Work® Certification™ - Business Wire
Functional Genomics Market Top PlayersExact Sciences - openPR.com
Exact Sciences Announces First-Quarter 2025 Results - ADVFN
Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report - Yahoo
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript - Insider Monkey
Exact Sciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences Corp Reports Strong Start to 2025 - TipRanks
Exact Sciences (EXAS) Target Price Raised by Barclays to $75 | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Price Target Raised by RBC Capital | EXAS Stock News - GuruFocus
Exact Sciences: Q1 Earnings Snapshot - GMToday.com
Lobbying Update: $470,000 of EXACT SCIENCES lobbying was just disclosed - Nasdaq
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - Barchart.com
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday - Benzinga
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS S - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS Stock News - GuruFocus
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance - Benzinga
Exact Sciences (EXAS) Price Target Raised to $72 by Baird Analys - GuruFocus
RBC Raises Price Target on Exact Sciences to $54 From $52, Keeps Sector Perform Rating - marketscreener.com
Exact Sciences (EXAS) Price Target Raised to $72 by Baird Analyst | EXAS Stock News - GuruFocus
S&P 500 Futures Rise in Premarket Trading; McCormick Vtg, Exact Sciences Lead - Barron's
Exact Sciences to Participate in May Investor Conference | EXAS Stock News - GuruFocus
Barclays Elevates Price Target for Exact Sciences (EXAS) to $75 - GuruFocus
Exact Sciences to Participate in May Investor Conference - Business Wire
Barclays Elevates Price Target for Exact Sciences (EXAS) to $75 | EXAS Stock News - GuruFocus
Exact Sciences Corp (EXAS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and New ... - Yahoo Finance
Exact Sciences Corp (EXAS) Q1 2025 Earnings Call Highlights: Str - GuruFocus
Exact Sciences reports Q1 EPS (54c) vs (60c) last year - TipRanks
Exact Sciences Reports Strong Q1 2025 Results - TipRanks
Exact Sciences Q1 2025 slides: revenue growth accelerates, profitability improves By Investing.com - Investing.com South Africa
Exact Sciences (EXAS) Boosts Revenue Outlook; Shares Rise Post-M - GuruFocus
Exact Sciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Exact Sciences Corp (EXAS) Q1 2025 Earnings: Revenue Surpasses E - GuruFocus
Exact Sciences Announces First-Quarter 2025 Results | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Surpasses Q1 2025 Expectations with 11% Re - GuruFocus
EXACT Sciences earnings missed by $0.21, revenue topped estimates - Investing.com South Africa
Exact Sciences Q1 2025 slides: revenue growth accelerates, profitability improves - Investing.com
Earnings call transcript: Exact Sciences Q1 2025 sees revenue growth, stock surges - Investing.com
Exact Sciences Q1 Adjusted Loss Narrows, Revenue Rises; Shares Up - marketscreener.com
Exact Sciences stock surges 8% on Q1 revenue beat, raised guidance By Investing.com - Investing.com South Africa
Exact Sciences stock surges 8% on Q1 revenue beat, raised guidance - Investing.com Canada
EXACT SCIENCES CORP SEC 10-Q Report - TradingView
Exact Sciences (EXAS) Q1 Revenue Beats Expectations, Raises Full-Year Outlook | EXAS Stock News - GuruFocus
Earnings Flash (EXAS) Exact Sciences Posts Q1 Revenue $706.8M, vs. FactSet Est of $688.6M - marketscreener.com
Exact Sciences Crushes Q1 Earnings: Revenue Surges 11%, Launches Revolutionary Cancer Detection Tests - Stock Titan
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):